Member Info for CHELSEA7

Dummy bid rising from 11.77 to 11.9

So a fair bit of activity in the lung cancer space lately, looking forward to our trial with CRUK very much. Markers hace been laid by others, we will know what data we will need and probably better following so many trials which have missed primary endpoints.

A nice trade yesterday, another 215k buy at 12.53, hoping to see that continue today. Have a good one.

As ever under the all seeng eye...............................

""Dr Ian Walker from Cancer Research UK said: “We’re pleased to see such promising early results.”

To answer your question .....
""When's our turn ?"" Well they keep reinststating trial will begin end of this year, we have been hearing of many promising treatments recently be good to see us the subject matter.

Nice buy today again, looking forward till tomorrow. Do we clear13 this week, that would be good.

Very good article TF

Surprisingly low number of patients in that Opvido trial, given how long they have been seeking that approval and the monies they have spent on it.

Might have to reconsider my level 2 subscription, got a really good feeling about us, seems like someone else has too.!!

Crikey. nice buy. I think that explains Fridays jump of .50p, where i expected to see a delayed trade yesterday on. There has been some very decent sized trades amongst very few trades and a pretty average volume. Nice to see I would of liked to have been able to see the register of late. Cenkos and Wins have been the main drivers of the SP of late.

Since early doors this morning the bid has been rising, now we know why. More to come?? Hope so. Night guys.

Yeah, just one sell on NEX 17K at 11.88, and last buy 10k at 12.40. Volume just 105k, buys 88k, so far. Don"t think bid has that high for weeks.

Till tomorrow, better feel about the share.

5 Trades...........All buys.

Thats all that is posted at the moment.

Nicely!!

That subject has been discussed here many times, over time. The negatives to it always seemed to outweigh the positives. Like many things it is all down to timing IMO. Not much is spoken about JC, I am pretty sure he knows when is the time. Speaking to a few others a while back opinions about him were quite split, I think given where we are, he has done a pretty good job here, given where we were when he was appointed. Anyone think differently?

Agree with that Ivy. According to last communacations with company, the trial will be starting by end 2018. Be interesting to see if SP reacts favourably to an RNS on that.

No , not since the one a few weeks ago which i posted, about what i perceived to be lack of updates.

Tend to agree with you there, just allowing timelines to happen when the BOD decide its right. Not sure what you mean by negativity, i thought everyone seems to be on the same page, maybe i missed a few.

I think we have a great chance of being in the money with Grand Challenge, that would allow so much clinical development to happen without more dilution. Not so sure we are ready to IPO just yet, lets see how our relationships develop first.

Genentech speaking.......................

o-located with the 19th World Vaccine Congress is the 3rd Immuno-oncology Profiling Congress (Oct 29 – 31 in Lisbon). The congress leverages on the abundance of our:
vaccinologists in cance
immuno-oncology
antibodies
check point inhibitors
neoantigens, adoptive T-cells therapies
CAR T-cells
oncolytic viruses or combinational methods.
Download the agenda now to see the full speaker list and agenda

New speakers recently confirmed:

Dr Carl Barrett
VP Translational Science, Oncology Innovative Medicine AstraZeneca Pharmaceuticals

Dr Ahmadur Rahman
Senior Clinical Director, Oncology European Clinical Development
MSD

Dr Jun Wang
Senior Medical Director, Cancer Immunotherapy
Genentech

Philip Beer
Physician Scientist and Precision Oncology Specialist
Wellcome Trust Sanger Institute

Dr Morena D'Alise
Lead Immunologist
Nouscom
DOWNLOAD THE LATEST AGENDA NOW
Make sure you attend the whole three days to also see our plenary sessions like:

Expectations and reality of cancer vaccines working: The impact of combinational approaches to immune-oncology therapies and more targeted responses
Development of novel therapies against cancer, based on vaccines, neoantigens, checkpoint inhibitors and adoptive T cell transfer
How close are these to actually treating patients? The translation of innovative therapeutic approaches into early clinical trials
Optimal methods of antigen delivery for vaccines in dendritic cells

Prof Dirk Jäger
Managing Director of Medical Oncology at the German National Cancer Center
University Hospital of Heidelberg

Dr Daniel Speisser Head of Clinical Tumour Biology and Immunotherapy Group, Department of Oncology and Ludwig Cancer Research Center
University of Lausanne

Dr Thomas G. Evans CEO
Vaccitech

Morning All.

https://www.investegate.co.uk/astrazeneca-plc--azn-/rns/az-s-tagrisso-approved-in-japan-for-1st-line-nsclc/201808210700093942Y/

Been good reading so many have considered our current associations as a big plus. Stay long, well i am, seems daft doing anything else TBH.

Goood find ivy, and interested in their take on China........................which as i said tonight i am finding very intersting. With talk of a Biotech bubble have they taken on the sheer size of users from China? I trust they have, a growth market if ive ever seen one.

China: A surge of investment
john carroll About five years ago, I started saying China is coming. And then I said the same thing the next year: China is coming. Next year, China is coming. Well, China is here, and in a big, big way. Everything is changing in China right now. Is this something that’s got legs? Is it a new world we’re going to be living with for a while? Because a lot of the research and development in China isn’t particularly well understood.

No probs. Was just trying to cover two points in one. Hence a new paragraph.Re the trades, i hadn"t noticed the delayed 100k was a minute or two before the first one posted. Not the first trades these past few weeks that are pretty hard to call.

Re posting any information on trades, even NEX, it came about during a "fierce conversation" i got embroiled in, so not sure if it is a new rule or just one that applies to me, lol. Bit daft really, rules seem to be ignored mostly, and then at a whim imposed. I understood a few had complained about it. Really!!! It was the day oldnotwise left, no surprises there for me. Take care.

Relevant to anybody interested in the emergence of China really, I am.

Out of sorts? Very. ATB

Thought we might get a delayed trade from Friday actually. The ask went up to 12.50? +.50p very quickly

Roses, ADMIN banned posting any trades, even NEX on Tuesday. Just one reason i cancelled Premium membership. FYI

Roses, you could be right, the delayed ttrade at 11.60 did precede the 100k at 11.80